Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-02-25
DOI
10.3389/fphar.2022.838133
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Management of tumor growth and angiogenesis in triple-negative breast cancer by using redox nanoparticles
- (2021) Babita Shashni et al. BIOMATERIALS
- Endothelial cell autophagy in homeostasis and cancer
- (2021) Jelle Verhoeven et al. FEBS LETTERS
- Cancer Stem Cells and Neovascularization
- (2021) Fengkai Li et al. Cells
- Breast cancer cell-derived extracellular vesicles transfer miR-182-5p and promote breast carcinogenesis via the CMTM7/EGFR/AKT axis
- (2021) Chong Lu et al. MOLECULAR MEDICINE
- The targetable nanoparticle BAF312@cRGD-CaP-NP represses tumor growth and angiogenesis by downregulating the S1PR1/P-STAT3/VEGFA axis in triple-negative breast cancer
- (2021) Ke Gong et al. JOURNAL OF NANOBIOTECHNOLOGY
- Vascular Normalization: A New Window Opened for Cancer Therapies
- (2021) Ting Yang et al. Frontiers in Oncology
- Potential Therapeutic Strategies for Lung and Breast Cancers through Understanding the Anti-Angiogenesis Resistance Mechanisms
- (2020) Wafaa S. Ramadan et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
- (2020) Paola Ciciola et al. Journal of Clinical Medicine
- An Overview of Vasculogenic Mimicry in Breast Cancer
- (2020) Marco A. Andonegui-Elguera et al. Frontiers in Oncology
- Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
- (2020) Yolla Haibe et al. Frontiers in Oncology
- Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores the angiogenic homeostasis and suppresses tumor progression.
- (2020) Antonio G. Solimando et al. HAEMATOLOGICA
- The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments
- (2020) Navid Sobhani et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial
- (2020) Luis Paz-Ares et al. Journal of Thoracic Oncology
- Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
- (2020) Jieqiong Liu et al. Journal for ImmunoTherapy of Cancer
- Interleukin-6-mediated epigenetic control of the VEGFR2 gene induces disorganized angiogenesis in human breast tumors
- (2020) Mangala Hegde et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Tumor Endothelial Cell–Mediated Antigen-Specific T-cell Suppression via the PD-1/PD-L1 Pathway
- (2020) Kazuhiro Taguchi et al. MOLECULAR CANCER RESEARCH
- ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment
- (2020) A Ianza et al. TUMOR BIOLOGY
- Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors
- (2020) Kayoko Hosaka et al. Nature Communications
- Correction: MicroRNA-140-5p inhibits invasion and angiogenesis through targeting VEGF-A in breast cancer
- (2020) Y. Lu et al. CANCER GENE THERAPY
- Docosahexaenoic acid (DHA) inhibits pro-angiogenic effects of breast cancer cells via down-regulating cellular and exosomal expression of angiogenic genes and microRNAs
- (2020) Cynthia Aslan et al. LIFE SCIENCES
- Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling
- (2020) Antonio Giovanni Solimando et al. Cancers
- Extracellular Vesicles Are Key Regulators of Tumor Neovasculature
- (2020) Naoya Kuriyama et al. Frontiers in Cell and Developmental Biology
- Hypoxic cancer–associated fibroblasts increase NCBP2-AS2/HIAR to promote endothelial sprouting through enhanced VEGF signaling
- (2019) Fernanda G. Kugeratski et al. Science Signaling
- Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models
- (2019) Sylvia Grünewald et al. INTERNATIONAL JOURNAL OF CANCER
- Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology
- (2019) Racheal G. Akwii et al. Cells
- Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study
- (2019) A. Mavratzas et al. BREAST
- Syndecan-1 facilitates breast cancer metastasis to the brain
- (2019) Megan R. Sayyad et al. BREAST CANCER RESEARCH AND TREATMENT
- Metformin inhibits metastatic breast cancer progression and improves chemosensitivity by inducing vessel normalization via PDGF-B downregulation
- (2019) Ji-Chang Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor–positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials
- (2019) M. Martín et al. EUROPEAN JOURNAL OF CANCER
- An oncogenic activity of PDGF-C and its splice variant in human breast cancer
- (2019) Alyssa Bottrell et al. GROWTH FACTORS
- Vascular Endothelial Cell Biology: An Update
- (2019) Krüger-Genge et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Gold nanoparticles and angiogenesis: molecular mechanisms and biomedical applications
- (2019) Ruba S. Darweesh et al. International Journal of Nanomedicine
- A shift from membranous and stromal syndecan‐1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer
- (2019) Simon Kind et al. MOLECULAR CARCINOGENESIS
- Functional inhibition of F11 receptor (F11R/junctional adhesion molecule-A/JAM-A) activity by a F11R-derived peptide in breast cancer and its microenvironment
- (2019) Radoslaw Bednarek et al. BREAST CANCER RESEARCH AND TREATMENT
- Tumor angiogenesis: causes, consequences, challenges and opportunities
- (2019) Roberta Lugano et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Low-dose anti-angiogenic therapy sensitizes breast cancer to PD-1 blockade
- (2019) Qian Li et al. CLINICAL CANCER RESEARCH
- CTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils
- (2019) Xichen Zheng et al. INTERNATIONAL JOURNAL OF CANCER
- Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment
- (2019) Raluca Ioana Teleanu et al. Journal of Clinical Medicine
- miR-153 inhibits the migration and the tube formation of endothelial cells by blocking the paracrine of angiopoietin 1 in breast cancer cells
- (2018) Huichun Liang et al. ANGIOGENESIS
- Consensus guidelines for the use and interpretation of angiogenesis assays
- (2018) Patrycja Nowak-Sliwinska et al. ANGIOGENESIS
- PDGF family function and prognostic value in tumor biology
- (2018) Michael Bartoschek et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- TGF-β signaling promotes tumor vasculature by enhancing the pericyte-endothelium association
- (2018) Justin Zonneville et al. BMC CANCER
- The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence
- (2018) Sara Jansson et al. BREAST CANCER RESEARCH AND TREATMENT
- Differential expression of IL-6/IL-6R and MAO-A regulates invasion/angiogenesis in breast cancer
- (2018) Rashmi Bharti et al. BRITISH JOURNAL OF CANCER
- Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study
- (2018) Ekaterini C. Tampaki et al. CLINICAL DRUG INVESTIGATION
- FGF Family: From Drug Development to Clinical Application
- (2018) Qi Hui et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Dipalmitoylphosphatidic acid inhibits breast cancer growth by suppressing angiogenesis via inhibition of the CUX1/FGF1/HGF signalling pathway
- (2018) Jian Chen et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
- (2018) Yazhuo Zhang et al. Molecular Cancer
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Hypoxia induces miR-153 through the IRE1α-XBP1 pathway to fine tune the HIF1α/VEGFA axis in breast cancer angiogenesis
- (2018) Huichun Liang et al. ONCOGENE
- Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models
- (2018) Kurt Schönfeld et al. PHARMACEUTICAL RESEARCH
- Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2
- (2018) Joao Incio et al. Science Translational Medicine
- Anti-Angiogenics: Current Situation and Future Perspectives
- (2018) Katja Zirlik et al. Oncology Research and Treatment
- Targeting VEGF/VEGFR to Modulate Antitumor Immunity
- (2018) Ju Yang et al. Frontiers in Immunology
- Pro- and antiangiogenic therapies: current status and clinical implications
- (2018) Ruslan Rust et al. FASEB JOURNAL
- Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node–Positive and High-Risk Lymph Node–Negative Breast Cancer (E5103)
- (2018) Kathy D. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of the interleukin (IL)-6/IL-6 receptor axis in cancer
- (2018) Mustafa Yassin Taher et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy with Bevacizumab and Erlotinib
- (2018) L. Symonds et al. Clinical Breast Cancer
- Interleukins as modulators of angiogenesis and anti-angiogenesis in tumors
- (2018) Domenico Ribatti CYTOKINE
- Prognostic and clinical significance of syndecan-1 expression in breast cancer: A systematic review and meta-analysis
- (2018) Weiqiang Qiao et al. EJSO
- Interleukin-8 Activates Breast Cancer-Associated Adipocytes and Promotes Their Angiogenesis- and Tumorigenesis-Promoting Effects
- (2018) Huda H. Al-Khalaf et al. MOLECULAR AND CELLULAR BIOLOGY
- Moving Breast Cancer Therapy up a Notch
- (2018) Erik W. J. Mollen et al. Frontiers in Oncology
- Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
- (2017) Lin Tian et al. NATURE
- Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer
- (2017) Linda T. Vahdat et al. ONCOLOGIST
- Circulating levels of angiogenesis-related growth factors in breast cancer: A study to profile proteins responsible for tubule formation
- (2017) Gemma A. Barron et al. ONCOLOGY REPORTS
- Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
- (2017) Martina Schmittnaegel et al. Science Translational Medicine
- Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
- (2017) Elizabeth Allen et al. Science Translational Medicine
- Involvement of breast cancer stem cells in tumor angiogenesis
- (2017) Yu Wang et al. Oncology Letters
- A class of extracellular vesicles from breast cancer cells activates VEGF receptors and tumour angiogenesis
- (2017) Qiyu Feng et al. Nature Communications
- Breast cancer metastasis: Putative therapeutic role of vascular cell adhesion molecule-1
- (2017) Rohit Sharma et al. CELLULAR ONCOLOGY
- Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy
- (2017) Audrey Bellesoeur et al. Drug Design Development and Therapy
- Tumor vasculogenic mimicry formation as an unfavorable prognostic indicator in patients with breast cancer
- (2017) Yanwei Shen et al. Oncotarget
- Nano-Hydroxyapatite-Derived Drug and Gene Co-Delivery System for Anti-Angiogenesis Therapy of Breast Cancer
- (2017) Lina Zhao et al. MEDICAL SCIENCE MONITOR
- Accomplices of the Hypoxic Tumor Microenvironment Compromising Antitumor Immunity: Adenosine, Lactate, Acidosis, Vascular Endothelial Growth Factor, Potassium Ions, and Phosphatidylserine
- (2017) Peter Vaupel et al. Frontiers in Immunology
- Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
- (2016) R. Bell et al. ANNALS OF ONCOLOGY
- Construction of a disulfide-stabilized diabody against fibroblast growth factor-2 and the inhibition activity in targeting breast cancer
- (2016) Yaxiong Cai et al. CANCER SCIENCE
- Gold nanoparticle-conjugated quercetin inhibits epithelial-mesenchymal transition, angiogenesis and invasivenessviaEGFR/VEGFR-2-mediated pathway in breast cancer
- (2016) S. Balakrishnan et al. CELL PROLIFERATION
- Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial
- (2016) Denise A. Yardley et al. Clinical Breast Cancer
- Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study
- (2016) Denise A. Yardley et al. Clinical Breast Cancer
- Clinical Pharmacokinetics and Pharmacodynamics of Cediranib
- (2016) Weifeng Tang et al. CLINICAL PHARMACOKINETICS
- Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival
- (2016) Jonas Kloepper et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer
- (2016) Domenico Ribatti et al. Translational Oncology
- Selective use of sorafenib in the treatment of thyroid cancer
- (2016) Fabián Pitoia et al. Drug Design Development and Therapy
- Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer
- (2016) Andrea L.A. Wong et al. Oncotarget
- Dual targeting of ANGPT1 and TGFBR2 genes by miR-204 controls angiogenesis in breast cancer
- (2016) Ali Flores-Pérez et al. Scientific Reports
- Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer
- (2015) Denise A. Yardley et al. BREAST CANCER RESEARCH AND TREATMENT
- FDA Approval Summary: Ramucirumab for Gastric Cancer
- (2015) S. J. Casak et al. CLINICAL CANCER RESEARCH
- Pericytes: a double-edged sword in cancer therapy
- (2015) Mao-Bin Meng et al. Future Oncology
- Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer
- (2015) John R. Mackey et al. JOURNAL OF CLINICAL ONCOLOGY
- 23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity
- (2015) T. Proia et al. MOLECULAR CANCER THERAPEUTICS
- miR-497 suppresses angiogenesis in breast carcinoma by targeting HIF-1α
- (2015) ZHIHAO WU et al. ONCOLOGY REPORTS
- Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models
- (2015) Xiao Yu Wu et al. Oncotarget
- Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation
- (2015) Alessia Brossa et al. Oncotarget
- Targeting Vascular Pericytes in Hypoxic Tumors Increases Lung Metastasis via Angiopoietin-2
- (2015) Doruk Keskin et al. Cell Reports
- Cycling Hypoxia Induces a Specific Amplified Inflammatory Phenotype in Endothelial Cells and Enhances Tumor-Promoting Inflammation In Vivo
- (2015) Céline Tellier et al. NEOPLASIA
- Macrophages are recruited to hypoxic tumor areas and acquire a Pro-Angiogenic M2-Polarized phenotype via hypoxic cancer cell derived cytokines Oncostatin M and Eotaxin
- (2015) Chakrapani Tripathi et al. Oncotarget
- Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease
- (2014) Mark D. Turner et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study
- (2014) Mark J. Clemons et al. BREAST CANCER RESEARCH AND TREATMENT
- Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study
- (2014) A. R. Tan et al. BREAST CANCER RESEARCH AND TREATMENT
- Cancer-Secreted miR-105 Destroys Vascular Endothelial Barriers to Promote Metastasis
- (2014) Weiying Zhou et al. CANCER CELL
- Antiangiogenesis Therapy for Breast Cancer: An Update and Perspectives from Clinical Trials
- (2014) Elham Fakhrejahani et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- MicroRNA-542-3p inhibits tumour angiogenesis by targeting Angiopoietin-2
- (2014) Ting He et al. JOURNAL OF PATHOLOGY
- Cooperation of DLC1 and CDK6 Affects Breast Cancer Clinical Outcome
- (2014) Xiaofeng Dai et al. G3-Genes Genomes Genetics
- MicroRNAs: Promising New Antiangiogenic Targets in Cancer
- (2014) Sandra Gallach et al. Biomed Research International
- Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer
- (2013) Matteo Clavarezza et al. BREAST
- Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer
- (2013) Giuseppe Curigliano et al. BREAST
- A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer
- (2013) Stephen R. D. Johnston et al. BREAST CANCER RESEARCH AND TREATMENT
- Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales
- (2013) Asmaa E El-Kenawi et al. BRITISH JOURNAL OF PHARMACOLOGY
- Vasculogenesis: a crucial player in the resistance of solid tumours to radiotherapy
- (2013) J M Brown BRITISH JOURNAL OF RADIOLOGY
- Heterogeneity of tumor endothelial cells
- (2013) Kyoko Hida et al. CANCER SCIENCE
- Phase I/II Trial of Vinorelbine and Sorafenib in Metastatic Breast Cancer
- (2013) Thehang Luu et al. Clinical Breast Cancer
- Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2-Negative Advanced Breast Cancer That Progressed during or after Bevacizumab
- (2013) L. S. Schwartzberg et al. CLINICAL CANCER RESEARCH
- Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study
- (2013) David M. Hyams et al. INVESTIGATIONAL NEW DRUGS
- Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer
- (2013) John P. Crown et al. JOURNAL OF CLINICAL ONCOLOGY
- Angiopoietin-2 mediates blood-brain barrier impairment and colonization of triple-negative breast cancer cells in brain
- (2013) Hava Karsenty Avraham et al. JOURNAL OF PATHOLOGY
- Effects of Vascular-Endothelial Protein Tyrosine Phosphatase Inhibition on Breast Cancer Vasculature and Metastatic Progression
- (2013) Shom Goel et al. JNCI-Journal of the National Cancer Institute
- Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
- (2013) David Cameron et al. LANCET ONCOLOGY
- Targeting Pericytes for Angiogenic Therapies
- (2013) Molly R. Kelly-Goss et al. MICROCIRCULATION
- miR-27a regulates endothelial differentiation of breast cancer stem like cells
- (2013) W Tang et al. ONCOGENE
- Tumor Endothelial Cells
- (2013) A. C. Dudley Cold Spring Harbor Perspectives in Medicine
- Endothelial Cell Heterogeneity
- (2013) W. C. Aird Cold Spring Harbor Perspectives in Medicine
- Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?
- (2013) Tom Donnem et al. Cancer Medicine
- The Role of Syndecan-1 in Cellular Signaling and its Effects on Heparan Sulfate Biosynthesis in Mesenchymal Tumors
- (2013) Tünde Szatmári et al. Frontiers in Oncology
- Methylseleninic acid restricts tumor growth in nude mice model of metastatic breast cancer probably via inhibiting angiopoietin-2
- (2012) Xiaojing Wu et al. BMC CANCER
- Phase II open-label study of sunitinib in patients with advanced breast cancer
- (2012) Denise A. Yardley et al. BREAST CANCER RESEARCH AND TREATMENT
- A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
- (2012) Massimo Cristofanilli et al. BREAST CANCER RESEARCH AND TREATMENT
- MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF
- (2012) Chao Zou et al. CELL CYCLE
- Vandetanib for the Treatment of Medullary Thyroid Cancer
- (2012) N. G. Chau et al. CLINICAL CANCER RESEARCH
- A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer
- (2012) William J. Gradishar et al. EUROPEAN JOURNAL OF CANCER
- HIF-mediated endothelial response during cancer progression
- (2012) Colin E. Evans et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells
- (2012) ATSUSHI MATSUMURA et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer
- (2012) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study
- (2012) Jonas Bergh et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
- (2012) Harry D. Bear et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
- (2012) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Sunitinib for the Treatment of Progressive Well-Differentiated Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors
- (2012) G. M. Blumenthal et al. ONCOLOGIST
- Fibroblast growth factors and their receptors in cancer
- (2011) Jørgen Wesche et al. BIOCHEMICAL JOURNAL
- Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c-Jun activation
- (2011) Anna N. Mendler et al. INTERNATIONAL JOURNAL OF CANCER
- Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer
- (2011) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2011) Adam M. Brufsky et al. JOURNAL OF CLINICAL ONCOLOGY
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- (2011) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
- The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab)
- (2011) Larry D. Sasich et al. SAUDI PHARMACEUTICAL JOURNAL
- An overview of the c-MET signaling pathway
- (2011) Shawna Leslie Organ et al. Therapeutic Advances in Medical Oncology
- Tumor Angiogenesis: Pericytes and Maturation Are Not to Be Ignored
- (2011) Elham Fakhrejahani et al. Journal of Oncology
- Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
- (2010) Carlos H. Barrios et al. BREAST CANCER RESEARCH AND TREATMENT
- Expression profile of IL-8 and growth factors in breast cancer cells and adipose-derived stem cells (ASCs) isolated from breast carcinoma
- (2010) Mahboobeh Razmkhah et al. CELLULAR IMMUNOLOGY
- Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
- (2010) Gang Niu et al. CURRENT DRUG TARGETS
- Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study
- (2010) Katalin Boér et al. INVESTIGATIONAL NEW DRUGS
- CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts
- (2010) Christophe Ginestier et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2010) David W. Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium
- (2010) S. K. Taylor et al. ONCOLOGIST
- Bevacizumab
- (2010) F. Kazazi-Hyseni et al. ONCOLOGIST
- Stromal Cell-Derived Factor-1/CXCL12 Contributes to MMTV-Wnt1 Tumor Growth Involving Gr1+CD11b+ Cells
- (2010) Bob Y. Liu et al. PLoS One
- The discovery of Hepatocyte Growth Factor (HGF) and its significance for cell biology, life sciences and clinical medicine
- (2010) Toshikazu NAKAMURA et al. PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
- Angiogenesis and Breast Cancer
- (2010) Adhemar Longatto Filho et al. Journal of Oncology
- Cytogenetic Abnormalities of Tumor-Associated Endothelial Cells in Human Malignant Tumors
- (2009) Tomoshige Akino et al. AMERICAN JOURNAL OF PATHOLOGY
- Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma
- (2009) R. C. Kane et al. ONCOLOGIST
- Sorafenib in the treatment of advanced hepatocellular carcinoma
- (2009) AliBen Mousa Saudi Journal of Gastroenterology
- Mechanisms of angiogenesis
- (2008) A. F. Karamysheva BIOCHEMISTRY-MOSCOW
- Anti-angiogenesis: making the tumor vulnerable to the immune system
- (2008) Arjan W. Griffioen CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Interleukin-8 Pathway in Cancer
- (2008) D. J.J. Waugh et al. CLINICAL CANCER RESEARCH
- Endothelial cell differentiation of human breast tumour stem/progenitor cells
- (2008) Benedetta Bussolati et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started